The study, led by Patrick Singleton, PhD, adds evidence that mu opioid receptors in cancer cells influence cancer progression and spread. These receptors could become a therapeutic target for cancer treatment.
Dr. Singleton’s findings also could influence surgical anesthesia used during cancer surgery.
More Articles on Anesthesia:
Anesthesia Machine Sales Expected to Increase by 2014
Dr. Brett Anderson Named Heritage Valley Chair of Anesthesiology
FDA Does Not Approve Zogenix’s Zohydro Opioid Pain Medication
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
